■ 자기소개
현재 한양대학교 의과대학에 재직 중인 허준영 교수는 한양대학교 의과대학을 졸업하고 성균관대학교에서 의학 박사학위를 취득하였다.
주요 진료와 연구분야는 고형암과 혈액암이며 국내외 학술지에 20여 편의 논문을 발표한 바 있다.
대한종양내과학회 한국암학술재단 학술상, 대한혈액학회 우수논문상을 수상하였다.
■ 학력
2009 한양대학교 의학사
2017 경희대학교 의학석사
2020 성균관대학교 의학박사
■ 경력
2009-2010 한양대학교병원 인턴
2010-2013 대한민국 군의관
2013-2017 경희의료원 내과 전공의
2018-2020 삼성서울병원 혈액종양내과 임상강사 (Fellow)
2020-2022 한양대학교 구리병원 혈액종양내과 임상조교수
2022- 현재 한양대학교 의과대학 내과학교실 조교수
■ 연구관심분야
고형암과 혈액암을 전문적으로 진료 및 연구하고 있습니다.
■ 주요논문
Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis. Blood Research 2021
Clinical significance of C-Reactive Protein to Lymphocyte Count Ratio as a prognostic factor for Survival in Non-small Cell Lung Cancer Patients undergoing Curative Surgical Resection. Journal of Cancer 2021
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. Immune network 2020
Regulatory (FoxP3+) T cells and TGF‑β predict the response to anti‑PD‑1 immunotherapy in patients with non‑small cell lung cancer. Scientific Reports 2020
Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single‐Center Experience. Cancers 2020
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. OncoImmunology 2020
Immune checkpoint inhibitors in patients with pretreated Hodgkin’s lymphoma: a Korean single-center, retrospective study. Blood Research 2020
Characteristics and clinical outcomes of non-small cell lung cancer patients in Korea With MET exon 14 skipping. In vivo 2020
Plasma Cell-Free DNA is a Prognostic Biomarker for Survival in Patients with Aggressive Non-Hodgkin Lymphomas. Annals of Hematology 2020
Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. Journal of Cancer 2020
High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathology-Research and Practice 2020
Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series. Precision and Future Medicine 2019
Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study. Cancer Research and Treatment 2019
■ 학회활동
대한암학회
대한내과학회
대한혈액학회
대한종양내과학회
대한항암요법연구회
미국암연구협회, American Association for Cancer Research (AACR)
미국혈액학회, American Society of Hematology (ASH)
대한종양내과학회 한국암학술재단 학술상, 2020
대한혈액학회 Blood Research 우수논문상, 2022